Torres-Lagares Daniel, Gutierrez-Perez Jose Luis, Hita-Iglesias Pilar, Magallanes-Abad Natale, Flores-Ruiz Rafael, Basallote-Garcia Marta, Gonzalez-Martin Maribel
Oral Surgery Department, University of Seville, Seville, Spain.
J Oral Maxillofac Surg. 2010 Jun;68(6):1322-6. doi: 10.1016/j.joms.2009.08.022. Epub 2010 Mar 25.
PURPOSE: Chlorhexidine (CHX) is an antimicrobial agent used in the prevention of tooth decay, periodontal disease, and postextraction alveolar osteitis (AO). Recently, a bioadhesive gel to deliver the active substance, CHX, was introduced. The intra-alveolar placement of the bioadhesive gel allows a more direct and prolonged therapeutic effect of CHX, which is useful in the prevention of AO after extraction of impacted third molars. The intra-alveolar application of the bioadhesive CHX gel in patients with bleeding disorders may increase the risk of postoperative bleeding complications. Inversely, bleeding disorders might influence the efficacy of CHX for AO prevention. The purpose of the present study was to evaluate the effectiveness of the bioadhesive 0.2% CHX gel in reducing the incidence of impacted third molar postextraction AO in patients with bleeding disorders. MATERIALS AND METHODS: We performed a double-blind, randomized, parallel-group study of 38 patients with bleeding disorders. The experimental group (n = 14) was treated with bioadhesive 0.2% CHX gel applied intraoperatively once after surgical removal of the third molar. The control group (n = 24) was treated in an identical fashion with placebo gel. RESULTS: We observed a 57.15% reduction in the incidence of AO in the experimental group. The control group had a 17% incidence of AO and the experimental group had a 7% incidence of AO (P = .402). Bleeding complications occurred in 21% of the experimental group compared with 29% of the control group (P = .601). CONCLUSIONS: As described in previous studies, the single intra-alveolar application of the bioadhesive 0.2% CHX gel in an intraoperative fashion seems to reduce the incidence of AO after removal of impacted third molars in patients with bleeding disorders. On the basis of the reported percentage of bleeding complications, the routine use of postoperative local hemostatic measures is recommended.
目的:洗必泰(CHX)是一种用于预防龋齿、牙周疾病和拔牙后干槽症(AO)的抗菌剂。最近,一种用于递送活性物质CHX的生物粘附凝胶被引入。生物粘附凝胶在牙槽内放置可使CHX产生更直接和持久的治疗效果,这对预防阻生第三磨牙拔除后的AO很有用。在有出血性疾病的患者中牙槽内应用生物粘附CHX凝胶可能会增加术后出血并发症的风险。相反,出血性疾病可能会影响CHX预防AO的疗效。本研究的目的是评估生物粘附0.2%CHX凝胶在降低有出血性疾病患者阻生第三磨牙拔除后AO发生率方面的有效性。 材料和方法:我们对38例有出血性疾病的患者进行了一项双盲、随机、平行组研究。实验组(n = 14)在手术拔除第三磨牙后术中应用一次生物粘附0.2%CHX凝胶进行治疗。对照组(n = 24)用安慰剂凝胶以相同方式治疗。 结果:我们观察到实验组AO发生率降低了57.15%。对照组AO发生率为17%,实验组为7%(P = 0.402)。实验组21%的患者发生出血并发症,而对照组为29%(P = 0.601)。 结论:如先前研究所述,术中单次牙槽内应用生物粘附0.2%CHX凝胶似乎可降低有出血性疾病患者拔除阻生第三磨牙后AO的发生率。根据报告的出血并发症百分比,建议常规使用术后局部止血措施。
Med Oral Patol Oral Cir Bucal. 2006-3-1
J Coll Physicians Surg Pak. 2012-2
Antibiotics (Basel). 2023-10-20
Cochrane Database Syst Rev. 2022-9-26
Med Oral Patol Oral Cir Bucal. 2018-11-1